botulinumtoxin

Xeomin Meets Primary Endpoint in Parallel Clinical Study

Xeomin Meets Primary Endpoint in Parallel Clinical Study

Merz Aesthetics has announced positive results from a post-market, parallel group clinical trial to evaluate the efficacy of Xeomin (incobotulinumtoxinA) in the treatment of moderate to severe glabellar facial lines when compared to Botox Cosmetic (onabotulinumtoxinA, Allergan). The trial met its primary efficacy endpoint, defined as ≥ 1-point improvement from baseline on the Facial Wrinkle Scale (FWS) at maximum frown one month after a single treatment.